Diagnostic Tools and Dilemmas With Equine Leukemias

Raskin, Rose E.

doi:10.1177/0300985817738315

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In bone marrow aspirate, the differential cell count was composed of 42% lymphoid cells, 5% differentiated myeloid cells, 24% erythroid cells (predominantly rubricytes and metarubricytes), and 29% blast cells with occasional plasma cells [ 17 ]. Because blast cells were difficult to differentiate based on morphology, cytochemical stains were used to determine the cell lineage to classify this process [ 18 ].…”

Section: Reviewmentioning

confidence: 99%

A review of current knowledge of myeloproliferative disorders in the horse

2021

View full text Add to dashboard Cite

Myeloid disorders are conditions being characterized by abnormal proliferation and development of myeloid lineage including granulocytes (neutrophils, eosinophils and basophils), monocytes, erythroids, and megakaryocytes precursor cells. Myeloid leukemia, based on clinical presentation and proliferative rate of neoplastic cells, is divided into acute (AML) and myeloproliferative neoplasms (MPN). The most commonly myeloid leukemia reported in horses are AML-M4 (myelomonocytic) and AML-M5 (monocytic). Isolated cases of AML-M6B (acute erythroid leukemia), and chronic granulocytic leukemia have also been reported. Additionally, bone marrow disorders with dysplastic alterations and ineffective hematopoiesis affecting single or multiple cell lineages or myelodysplastic diseases (MDS), have also been reported in horses. MDSs have increased myeloblasts numbers in blood or bone marrow, although less than 20%, which is the minimum level required for diagnosis of AML. This review performed a detailed description of the current state of knowlegde of the myeloproliferative disorders in horses following the criteria established by the World Health Organization.

show abstract

Section: Reviewmentioning

confidence: 99%